Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Nonsmall Cell Lung Cancer Stage III · Unresectable Non-Small Cell Lung Carcinoma · Nonsmall Cell Lung Cancer, Stage II

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Contact: Study coordinator (Jada Kluttz) · Jada.Kluttz@Advocatehealth.org · 336-713-0901
Contact: Principal Investigator (Thomas Lycan, MD)

Study leads

Thomas Lycan, MD
Principal Investigator
Wake Forest Baptist Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Cleveland, United States

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

NSCLC (Non-small Cell Lung Carcinoma) · Stage III · EGFR Uncommon Mutations

Abroad (travel likely)RecruitingPHASE2

Changsha, China

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

Lung Cancer Stage III

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Lung Cancer Stage III · Mutation

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China